Antibody drug conjugates (ADCs) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADCs of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
